BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
BioAge Labs, a clinical-stage biopharmaceutical company, will host an R&D Day webcast on May 8, 2026, presenting Phase 1 clinical data and the development rationale for BGE-102, a novel NLRP3 inflammasome inhibitor. The presentation includes insights from leading experts on NLRP3 biology and potential treatments for atherosclerotic cardiovascular d…